CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
Groundbreaking new methodology published in Nature Medicine uncovers the missing numbers to the only clock that really matters in the body – your immune age
CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery
New CytoReason machine learning model turns mice into men (and women) to overcome the barrier of cross-species differences in drug development, published in Nature Methods
CytoReason: New machine learning driven findings uncover new cellular players in tumor micro-environment that might point the way to improved immunotherapy for refractory melanoma patients
CytoReason’s unique immune-focused AI model creates the largest library of inter-cellular communications – uses it to predict 335 novel cell-cytokine interactions, new clues for drug development
CytoReason cements proof-of-concept with machine learning-facilitated biomarker breakthrough in anti-TNFα treatment failure in inflammatory bowel disease. New data published in Gut
